| Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug … T Shao, M Zhao, L Liang, W Tang BioDrugs 37 (3), 421-432, 2023 | 17 | 2023 |
| Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China T Shao, Y Ren, M Zhao, W Tang Frontiers in Public Health 10, 912921, 2022 | 15 | 2022 |
| Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma T Shao, M Zhao, W Tang Frontiers in Oncology 12, 953671, 2022 | 12 | 2022 |
| Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: a network meta-analysis T Shao, L Liang, C Zhou, Y Tang, W Gao, Y Tu, Y Yin, DC Malone, ... Frontiers in Public Health 10, 1051581, 2023 | 11 | 2023 |
| Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non … M Zhao, T Shao, Z Chi, W Tang Frontiers in Public Health 11, 1051484, 2023 | 10 | 2023 |
| A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer T Shao, M Zhao, L Liang, W Tang Frontiers in Immunology 13, 948597, 2022 | 9 | 2022 |
| Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network … M Zhao, T Shao, Y Ren, C Zhou, W Tang Frontiers in Pharmacology 13, 910656, 2022 | 9 | 2022 |
| Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis Y Li, Y Lin, Z Shi, Y Hu, T Shao, M Li, J Zhu, L Sun, F Chang Annals of Translational Medicine 9 (18), 2021 | 6 | 2021 |
| Effectiveness and efficiency of non-drug therapy among community-dwelling adults with hypertension in China: a protocol for network meta-analysis and cost-effectiveness analysis T Shao, X Li, C Zhou, X Zang, DC Malone, L Zhang, J Zhou, W Tang Frontiers in Medicine 8, 651559, 2021 | 5 | 2021 |
| Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: a case study of checkmate 067 T Shao, M Zhao, L Liang, L Shi, W Tang PharmacoEconomics-Open 7 (3), 383-392, 2023 | 3 | 2023 |
| EPH172 when is it valuable for COVID-19 booster dose?: a transmission dynamics model-based effectiveness and cost-effectiveness analysis of two booster dose vaccination … D Zhou, T Shao, H Shao, Y Tu, Y Tang, J Zhou, DC Malone, W Tang Value in Health 25 (7), S466, 2022 | 3 | 2022 |
| Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes Y Hu, Y Wang, T Shao, W Tang, K Hu, Y Zhou, L Miao, J Liu, B Wang, ... Vaccine 41 (18), 3003-3010, 2023 | 1 | 2023 |
| A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases Y Jiang, T Shao, M Zhao, Y Xue, X Zheng Frontiers in Pharmacology 15, 1374136, 2024 | | 2024 |
| Identifying optimal ALK inhibitors in first-and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta … M Zhao, T Shao, H Shao, C Zhou, W Tang BMC cancer 24 (1), 186, 2024 | | 2024 |
| A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced … H Shao, M Zhao, AJ Guan, T Shao, D Zhou, G Yu, W Tang BMC medicine 22 (1), 13, 2024 | | 2024 |
| Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method Q Peng, Y Yin, M Liang, M Zhao, T Shao, Y Tang, Z Mei, H Li, W Tang Cost Effectiveness and Resource Allocation 21 (1), 80, 2023 | | 2023 |
| Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China L Liang, T Shao, H Li, M Zhao, W Tang BMC Public Health 23 (1), 1531, 2023 | | 2023 |
| Age priority in continuous coronavirus disease 2019 booster doses under China's new policy of free-will nucleic acid test: A dynamic model-based effectiveness and cost … D Zhou, T Shao, H Shao, Y Tu, M Zhao, K Zhou, K Wang, X Tang, Z Liu, ... Health Decision 1, 2023 | | 2023 |
| Different vaccination strategies for preventing coronavirus disease 2019 in Kenya: A dynamic modelling study of health impact and cost-effectiveness D Zhou, H Shao, Y Tu, T Shao, M Zhao, K Zhou, K Wang, X Tang, Y Xing, ... Health Decision 1, 2023 | | 2023 |
| Traditional Chinese medicine in treating corona virus disease 2019: A systematic review and cost-effectiveness analysis T Shao, K Wang, X Liao, W Tang Health Decision 1, 2023 | | 2023 |
Wenxi TangChina Pharmaceutical University在 cpu.edu.cn 的电子邮件经过验证
Wenxi TangChina Pharmaceutical University在 cpu.edu.cn 的电子邮件经过验证